Lung Cancer Screening Adherence After Baseline Screening Is Lower Than Reported

Patients who undergo baseline lung cancer screening are less likely to adhere to screening recommendations compared with the screening rates of patients who participate in randomized clinical trials, according to a meta-analysis now published in JAMA Network Open. Undergoing regular cancer screening has been shown to reduce the risk of cancer mortality. Data from the 2018 National Health Interview Survey found that approximately 70% of eligible women underwent breast cancer screening within the ...
Continue reading

Brigatinib More Effective Than Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

A second interim analysis of the phase 3 ALTA-1L trial shows that brigatinib demonstrates superior results in patients with advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer (NSCLC) compared with crizotinib. Crizotinib is not the most effective therapy for patients with ALK-positive NSCLC, as disease progression occurs frequently in the central nervous system, possibly due to poor drug penetration. In previous phase 1/2 trials, brigatinib, a next-generation ALK inhibitor with ...
Continue reading

Capmatinib Approved: Metastatic Non-Small Cell Lung Cancer

The FDA has granted accelerated approval to capmatinib (TabrectaTM, Novartis) for adults with metastatic non­-small cell lung cancer (NSCLC) with mutations that lead to mesenchymal-epithelial transition (MET) exon 14 skipping. In addition, the FDA approved the FoundationOne® CDx (F1CDx) assay (Foundation Medicine, Inc.) as a companion diagnostic. Approval was based on the phase 2 GEOMETRY mono-1 trial (NCT02414139), a multicenter, nonrandomized trial evaluating capmatinib in patients with MET ex...
Continue reading

Lung Cancer Screening Program Websites: Faulty Advertising?

Although lung cancer screening can help to save lives, it is not without significant risks. Patients need to be given information about both benefits and risks so that they can make an informed decision regarding whether to undergo screening. However, an analysis of screening program websites has now shown that many provide a biased, overly positive perspective of screening rather than a well-balanced portrayal of risks and benefits. The National Lung Screening Trial found that screening with lo...
Continue reading

Pembro/Pemetrexed-Platinum: How Does It Affect Patient QOL?

In patients with previously untreated, metastatic, non-squamous non-small cell lung cancer (NSCLC), pembrolizumab plus pemetrexed-platinum has proven to be an effective treatment compared with pemetrexed-platinum alone in increasing the proportion of patients who experience a complete or partial response, as shown in the KEYNOTE-189 study. Based on the results of this study, the FDA recently approved a new indication for pemetrexed in this combination for the first-line treatment ...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.